Every meaningful FDA action affecting GLP-1 medications.

SURMOUNT-MAINTAIN is the first randomised trial designed specifically to test whether a lower maintenance dose can hold weight loss achieved at a higher one. Published in The Lancet on 12 May 2026 (doi:10.1016/S0140-6736(26)00656-2), the phase 3b trial ran 112 weeks across 20 US sites, enrolling 441 participants and randomising 378 at week 60.

Only participants who had reached a defined plateau — less than 5% bodyweight change between weeks 48 and 60 on their maximum tolerated dose of 10 mg or 15 mg — entered the randomised phase. They were assigned to continue at that dose, reduce to 5 mg, or switch to placebo.

At week 112, the continuation arm maintained a 21.9% bodyweight reduction, the reduced-dose arm 16.6%, and the placebo arm 9.9%. Both active arms beat placebo at p<0.0001, with estimated treatment differences of −12.0 and −6.6 percentage points respectively.

The practical significance is that stepping down is now an evidence-supported option rather than an untested guess. It is not free: roughly a quarter of the maintained reduction was given up. For patients whose obstacle is cost or tolerability, that trade may be clearly better than stopping — which SURMOUNT-4 showed produces substantial regain. Dose changes remain prescriber decisions.

Source: SURMOUNT-MAINTAIN in The Lancet

SURPASS-CVOT, published in the New England Journal of Medicine in December 2025 (2025;393:2409-2420, doi:10.1056/NEJMoa2505928, PMID 41406444), randomised 13,299 adults with type 2 diabetes and established atherosclerotic cardiovascular disease to tirzepatide or dulaglutide, following them for a median of four years.

The primary composite of cardiovascular death, myocardial infarction or stroke occurred in 12.2% of the tirzepatide group and 13.1% of the dulaglutide group. That difference met the pre-specified noninferiority threshold (p=0.003) but did not meet superiority (p=0.09).

The design matters. Most cardiovascular outcome trials use placebo control, which answers whether a drug beats nothing. SURPASS-CVOT used an active comparator that already carries its own cardiovascular indication, so noninferiority here is a considerably harder result than it would be against placebo.

Reported secondary analyses described larger reductions in blood pressure and lipids and a mortality signal favouring tirzepatide, with subsequent analyses reporting reduced major kidney events. Secondary endpoints carry less inferential weight than the pre-specified primary. Claims that the trial proved tirzepatide superior for heart protection overstate what was found.

Source: SURPASS-CVOT in NEJM

Eli Lilly's direct channel prices Zepbound single-dose vials at $299 per month for the 2.5 mg starting dose, $399 at 5 mg, and $449 at 7.5 mg and above. The tier flattens at 7.5 mg, so reaching a higher maintenance dose does not continue to raise the monthly figure.

Against a retail list price in the region of $1,086, the direct channel represents a saving of roughly $637 a month at the maintenance tier — the largest single cost lever available to an uninsured patient, and one requiring no appeal or documentation.

Two conditions catch people out. The channel is cash-only and cannot be billed to insurance, so it cannot contribute to a deductible or out-of-pocket maximum. And at 7.5 mg and above, holding the lowest price requires refilling within 45 days; supply interruptions, travel, or waiting on a prescriber appointment can push a patient past that window.

For anyone with commercial insurance, this remains the fallback rather than the first move. A covered benefit with a manufacturer savings programme typically produces a far smaller monthly figure, which is why establishing coverage position — and appealing a denial — usually returns more than comparing cash prices.

Source: Eli Lilly pricing announcement

The FDA approved Zepbound for moderate-to-severe obstructive sleep apnoea in adults with obesity on 20 December 2024, making it the first medication ever approved for OSA. Approval rested on SURMOUNT-OSA (NCT05412004), two 52-week randomised placebo-controlled trials in 469 adults, one arm using positive airway pressure therapy and one not.

The coverage significance follows from how benefits are structured rather than from the clinical result. Many employer plans exclude anti-obesity medication as a category, and when that carve-out exists no amount of BMI documentation produces coverage — the criteria were never the obstacle.

Obstructive sleep apnoea sits elsewhere in the benefit design. It is a diagnosed sleep disorder with an objective diagnostic test and a long history of insured treatment, and plans excluding weight-management drugs frequently cover it.

Requests generally need a sleep study documenting an apnoea-hypopnoea index of 15 or higher, usually within twelve months, together with documented obesity and a prescriber statement naming the OSA indication rather than describing weight loss as the goal. Letters framed around weight get routed back to the excluded criteria — which is where otherwise-sound requests fail.

Source: FDA approval announcement

Compounding of tirzepatide and semaglutide was lawful only while the molecules sat on the FDA drug shortage list. The tirzepatide shortage was declared resolved on 2 October 2024 and reaffirmed by declaratory order on 19 December 2024; enforcement discretion ended 18 February 2025 for 503A pharmacies and 19 March 2025 for 503B outsourcing facilities. A federal court upheld the determination in May 2025.

Despite that, sellers continue to market compounded versions, commonly on the argument that adding an ingredient — vitamin B12 is the usual example — or varying the dose slightly produces something that is not a copy. The FDA has treated preparations within a narrow range of the approved dose as essentially copies regardless of such additions.

For consumers the useful test is narrower than the legal argument. A 'personalised' label establishes neither lawful supply nor product quality, and no randomised trial has ever evaluated any compounded GLP-1 preparation. Every efficacy figure in circulation belongs to the approved product.

The two questions worth asking any seller still advertising these products are what legal basis it operates under, and which state-licensed pharmacy dispenses, by legal name and licence number. The second is checkable against a state board register in minutes, and a refusal to answer before payment is itself informative.

Source: FDA declaratory order on tirzepatide shortage

On April 30, 2026, the FDA announced a proposal to exclude semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Victoza, Saxenda) from the 503B bulks list, stating there is no current clinical need for outsourcing facilities to compound these medications from bulk drug substances. The agency has opened a public docket and will weigh submitted comments before a final determination.

The 503B bulks list governs which bulk active ingredients large-scale outsourcing facilities may compound. With the tirzepatide (October 2024) and semaglutide (February 2025) shortages already resolved, the shortage-based compounding pathway had closed; this proposal would foreclose the 503B bulk route as well, even if a new shortage were later declared.

Important scope note: the proposal targets 503B outsourcing facilities. Patient-specific compounding by state-licensed 503A pharmacies operates under a separate legal framework, though that framework also restricts compounding that is "essentially a copy" of an available FDA-approved drug.

Eli Lilly confirmed that orforglipron — branded Foundayo following FDA approval in March 2026 — completed its pre-launch cardiovascular safety analysis without new signals. Commercial supply for the obesity indication is expected to enter pharmacies in Q4 2026, with the diabetes indication launch following.

Orforglipron is the first oral, small-molecule (non-peptide) GLP-1 receptor agonist. Unlike semaglutide tablets (Rybelsus), which use the absorption enhancer SNAC and have strict food-and-water dosing requirements, orforglipron is a true small molecule with conventional oral pharmacokinetics. The phase 3 ATTAIN-1 trial in obesity (without diabetes) showed weight loss of approximately 12.4% at the 36 mg dose at 72 weeks.

State pharmacy boards in Florida, Texas, and California have opened formal investigations into several high-volume 503A compounding pharmacies producing semaglutide and tirzepatide preparations at scale. The actions follow clusters of adverse events linked to specific batches and concerns about whether 503A operations dispensing nationally are operating within their statutory scope.

Under federal law, 503A pharmacies prepare compounded medications for individual patients with valid prescriptions and are exempt from FDA new-drug approval requirements. 503B "outsourcing facilities" can produce in bulk for clinical use but must comply with cGMP standards. The boundary becomes contested when 503A pharmacies dispense at high volume to patients identified through online telehealth platforms.

The FDA's enforcement transition period for 503B outsourcing facility production of compounded semaglutide and tirzepatide has fully concluded. With both drugs formally off the shortage list, 503B facilities are no longer permitted to produce these molecules in bulk under the Section 503B exemption.

This change does not affect Section 503A patient-specific compounding when a clinician determines an FDA-approved product is not suitable for an individual patient — for example, due to documented allergy to an inactive ingredient, dose adjustments not available in the commercial product, or sterility concerns. Most telehealth programs operating at scale rely on 503A pathways for ongoing GLP-1 compounding, with clinical documentation supporting the individualized determination.

CMS guidance now supports Part D coverage of semaglutide 2.4 mg (Wegovy) for the cardiovascular event-reduction indication granted by FDA in March 2024, for Medicare beneficiaries with BMI ≥27 and established cardiovascular disease. Coverage for weight management alone remains statutorily excluded.

The practical effect is that Medicare beneficiaries who previously could not obtain Wegovy through Part D may now be eligible if they meet the SELECT-aligned criteria: prior MI, prior ischemic stroke, or symptomatic peripheral artery disease, plus BMI in the overweight or obese range. Documentation of the CV indication is required at the prior authorization step.

The FDA outlined plans to restrict certain ingredients used in mass-marketed compounded GLP-1 medications and to step up enforcement against misleading advertising on direct-to-consumer telehealth platforms. The action follows a sustained pattern of patient adverse-event reports tied to non-FDA-approved formulations of semaglutide and tirzepatide sold by retail compounders.

The agency restated its longstanding position that compounded drugs do not undergo FDA premarket review for safety, effectiveness, or quality, and should be used only when medically necessary — preferably with prescriptions filled at state-licensed pharmacies rather than at compounding operations running at scale. FDA also flagged concerns specific to compounded GLP-1s, including improper cold-chain storage during shipping and inconsistent potency between batches when 503A pharmacies operate without rigorous third-party testing.

The FDA approved orforglipron under the brand name Foundayo on April 1, 2026 for adults with obesity, or adults with overweight and at least one weight-related health condition. Foundayo is the second oral GLP-1 approved for weight loss — following oral semaglutide (Wegovy) in December 2025 — and the first small-molecule, non-peptide oral GLP-1 receptor agonist approved by the agency. Unlike oral Wegovy, Foundayo can be taken at any time of day with no food or water restrictions.

Notably, the FDA reviewed the Foundayo application in 50 days under the Commissioner's National Priority Voucher pilot program. Typical new-drug approvals take six to ten months. Foundayo is the fifth approval issued under the CNPV pilot and the first approval of a new molecular entity under the program, making it the fastest NME approval since 2002.

In Lilly's ATTAIN-1 trial, patients on the highest dose who completed the trial lost an average of 27.3 lb (12.4% of body weight), versus 2.2 lb (0.9%) on placebo. Common side effects mirror other GLP-1s — nausea, constipation, diarrhea, vomiting, and reflux — and the label carries a class boxed warning for thyroid C-cell tumors. Self-pay through LillyDirect starts at $149/month for the lowest dose; eligible commercially-insured patients may pay as little as $25/month with the savings card.

Following a months-long review of the company's website between January and March 2026, the FDA determined that products sold by Gram Peptides — including substances marketed under labels such as "Retatrutide" (referred to internally as "GLP-1-R peptide"), "Tirzepatide" ("GLP-2 peptide"), and bacteriostatic water for injection — qualify as unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act.

The warning is significant for the broader gray-market peptide trade. Vendors that sell GLP-1 analogs as "research use only" while clearly marketing them for human therapeutic use are now being targeted directly. The same legal theory threatens dozens of similar online sellers operating in this space.

The FDA approved a label expansion for Zepbound (tirzepatide) authorizing a four-dose, single-patient-use KwikPen that delivers a full month of treatment in one device for chronic weight management. Patients with a valid prescription opting for self-pay through LillyDirect can now receive tirzepatide in either the KwikPen or single-dose vial format starting at $299/month for the 2.5 mg dose; 5 mg through 15 mg doses are priced at higher tiers.

The therapeutic active ingredient is identical across Zepbound presentations — only the delivery vehicle changes. Lilly framed the multi-dose option as expanding flexibility for patients and clinicians to choose the format that fits individual needs.

On February 6, 2026, the FDA published a press announcement signaling formal enforcement action against non-FDA-approved GLP-1 drugs. The announcement clarified the agency's posture during the post-shortage period: while GLP-1 supply has stabilized, certain compounding pharmacies and gray-market vendors continue to distribute products that fall outside the legal compounding framework.

FDA paired the announcement with patient guidance recommending that compounded drugs be used only when medically necessary, and that patients fill prescriptions at state-licensed pharmacies rather than at large-scale compounding operations. The agency also pointed patients to the BeSafeRx campaign for guidance on safely buying prescription medications online.

In September 2023, the FDA moved a long list of peptides — including BPC-157, Thymosin Beta-4, CJC-1295, Ipamorelin, and Sermorelin — to Category 2 ("substances with safety concerns") on the 503A bulk drug substances list. That single regulatory action ended most legal bulk compounding of those peptides almost immediately.

Through 2025, industry groups, clinicians, and several state attorneys general formally asked HHS to reopen the review, citing what they described as inconsistent application of "safety concern" criteria across drug classes. New HHS leadership has since asked FDA to publish more data on how shortages are determined and to address access concerns; the 2026 budget request includes language directing FDA to publish more transparent shortage criteria.

FDA-approved prescribing information for both Zepbound (tirzepatide for weight loss) and Mounjaro (tirzepatide for type 2 diabetes) was updated in January 2026 to include multi-use vial presentations alongside the existing pen and single-dose vial formats. Each multi-use vial contains four weekly doses; patients draw up one dose each week using an insulin-style syringe — the same workflow used in many medical weight-loss programs.

The change formalizes a delivery format that compounded GLP-1 providers have used for years. For patients already comfortable with vial-format Zepbound, the official label change is a regulatory affirmation that this dosing method is now part of Lilly's long-term treatment model.

Following earlier label expansions for cardiovascular risk reduction (the SELECT trial) and other metabolic indications, Wegovy received an expanded FDA indication for metabolic dysfunction-associated steatohepatitis (MASH), the disease formerly known as NASH. MASH is a leading cause of liver transplantation in the U.S. and previously had no approved pharmacotherapy beyond resmetirom.

The MASH indication reflects a broader shift in how regulators view GLP-1 receptor agonists: not only as weight-loss agents, but as systemic metabolic therapeutics with measurable impact on cardiovascular outcomes, sleep apnea, kidney disease, and now liver pathology.

The FDA approved Zepbound (tirzepatide) for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity, alongside a reduced-calorie diet and increased physical activity. The approval was based on the phase 3 SURMOUNT-OSA trials, which evaluated 10 mg or 15 mg tirzepatide doses against placebo in patients with or without positive airway pressure (PAP) therapy.

The mechanism is indirect: weight loss reduces the airway obstruction that drives sleep apnea, and the effect sizes seen in SURMOUNT-OSA — meaningful reductions in hourly breathing disruptions and substantial weight loss across both PAP and non-PAP subgroups — were large enough to support the indication. Following approval, several major insurance carriers updated their formularies to cover tirzepatide for the OSA indication, typically requiring a documented diagnosis through a sleep study and a BMI of 30 or higher.

FDA confirmed in late 2024 that the tirzepatide shortage that began in 2022 had been resolved, with the manufacturer reporting that product availability and manufacturing capacity meet present and projected national demand. Enforcement discretion for compounders ended on the following published timeline:

• Tirzepatide: 503A pharmacies — February 18, 2025; 503B outsourcing facilities — March 19, 2025.
• Semaglutide: 503A pharmacies — April 22, 2025; 503B outsourcing facilities — May 22, 2025.

FDA reminded compounders that compounded drugs are not approved by the agency, do not undergo premarket review for safety, effectiveness, or quality, and may only be compounded under patient-specific clinical justification — not for mass distribution. Patients and prescribers may still see intermittent localized supply disruptions as products move through the supply chain, but the structural shortage is over.